News
IXICO wins "CRO Provider of the Year 2025" at the Precision Medicine Awards!
We’re proud to announce that IXICO has been named CRO Provider of the Year at the Precision Medicine Awards 2025, hosted by Oxford Global. This award celebrates our commitment to advancing precision in neuroscience through cutting-edge neuroimaging and AI-powered analytics.
Global clinical trial contract wins in Alzheimer’s Disease and Friedreich’s Ataxia
12 August 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications.
IXICO and Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership for the Transformative Bio-Hermes-002 Study
IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias London, UK July.
Revenues anticipated to be ahead of expectations for the year ending 30 September 2025
17 July 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today provides a trading update for the financial year ending 30 September 2025. The Company anticipates revenues to be at least £6.
IXICO assists first FDA clearance of new Alzheimer’s Disease blood based diagnostic biomarker
10 June 2025 IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today outlined its role in the validation of a new Alzheimer’s Disease (AD) diagnostic biomarker for client Fujirebio Diagnostics, Inc.
Interim results for six months ending 31 March 2025
20 May 2025 IXICO plc (AIM: IXI), a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announces its unaudited interim results for the six months ended 31 March 2025 (‘H1 2025’ or the ‘period’). Financial highlights Revenues up 26% to £3.
Half-year Trading update - FY2025
16 April 2025: IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience, today provides a trading update ahead of its interim results for the six months ended 31 March 2025.
Contract Wins in Alzheimer’s and Huntington’s Disease
27 February 2025 - London, UK. IXICO plc (AIM: IXI, “IXICO” or “the Company”) a global leader in neuroscience imaging, using its AI-driven platform to help advance therapy research in neurological disorders, today announces that it has signed a new commercial contract for a global Alzheimer’s Disease (AD) imaging analysis with a leading biotechnology company, and secured an additional project in Huntington’s Disease (HD) with an existing partner.
1-8 of 26 results